

NEOTHERAPEUTICS INC

Form 8-K

June 03, 2002

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES AND EXCHANGE ACT OF 1934**

May 30, 2002

Date of Report (Date of earliest event reported)

**NEOTHERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other Jurisdiction  
of Incorporation)

**157 Technology Drive  
Irvine, California**

(Address of principal executive offices) **92618**  
(Zip Code)

**000-28782**  
(Commission File Number)

**93-0979187**  
(IRS Employer  
Identification Number)

**(949) 788-6700**  
(Registrant's telephone number, including area code)

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

**Item 5. Other Events.**

On May 30, 2002, NeoTherapeutics, Inc. issued a news release announcing the interim results from its pilot study of Neotrofin in patients with early-stage Parkinson's disease. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference.

**Item 7. Exhibits**

Exhibits:  
99.1 Press  
Release  
dated  
May 30,  
2002.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOTHERAPEUTICS, INC.

Date: June 3, 2002

By:

Name:

Title: /s/ Samuel Gulko

---

Samuel Gulko

Senior Vice President

Finance,

Chief Financial Officer,

Secretary and Treasurer

---

Edgar Filing: NEOTHERAPEUTICS INC - Form 8-K

Exhibit  
Number

99.1 Press Release dated  
May 30, 2002.

Document Description